drug
enzalutamide
Marketedupdated 6mo agoby Alessa Therapeutics Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Prostate Cancer
all catalysts(28)
approval · 28
Aug 31, 2012
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Mar 19, 2013
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
May 23, 2014
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Sep 10, 2014
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Jul 21, 2015
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Aug 5, 2015
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Oct 1, 2015
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Nov 6, 2015
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Jul 14, 2016
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Oct 20, 2016
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Jul 24, 2017
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Jul 13, 2018
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Dec 16, 2019
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Aug 4, 2020
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Oct 23, 2020
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
May 24, 2021
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Jan 13, 2022
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Jan 13, 2022
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Sep 9, 2022
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Sep 9, 2022
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Nov 16, 2023
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Nov 16, 2023
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Jan 22, 2025
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Jan 22, 2025
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Mar 21, 2025
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Mar 21, 2025
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Dec 11, 2025
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Dec 11, 2025
approval
XTANDI (ENZALUTAMIDE) — FDA approval
enzalutamide
→
Trials studying enzalutamide
- phase2An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- phase2Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- phase3Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- phase2Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
- phase2The COSMYC Trial (COmbined Suppression of MYC)
- phase1A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- phase3An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 13, 2027
264 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (17)
- Feb 23, 2037method-of-use (U-4104)US 12161628
- Feb 23, 2037method-of-use (U-4104)US 12161628
- Feb 23, 2037method-of-use (U-4101)US 12161628
- Sep 11, 2033formulationUS 11839689
- Sep 11, 2033formulationUS 11839689
- Sep 11, 2033method-of-use (U-4314)US 12447128
- Sep 11, 2033method-of-use (U-4365)US 12502357
- Sep 11, 2033method-of-use (U-4365)US 12502357
- Aug 13, 2027compositionUS 7709517264d
- Aug 13, 2027compositionUS 7709517264d
- Aug 13, 2027compositionUS 7709517264d
- Aug 24, 2026method-of-use (U-3763)US 8183274
- Aug 24, 2026method-of-use (U-3763)US 8183274
- Aug 24, 2026method-of-use (U-3763)US 8183274
- May 15, 2026method-of-use (U-3763)US 9126941
- May 15, 2026method-of-use (U-3763)US 9126941
- May 15, 2026method-of-use (U-3763)US 9126941
FDA exclusivities (3)
- Nov 17, 2026I-926Indication (3y)
- Nov 17, 2026I-926Indication (3y)
- Nov 17, 2026I-926Indication (3y)
News(8)
- AstraZeneca cuts early-phase prostate cancer pipelineAstraZeneca has punted a pair of early-phase prostate cancer programs as part of its quarterly pipeline clear out.fiercebiotech · 22d ago
- Lilly shuffles business structure; Novartis writes off part of Avidity dealLilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.biopharma_dive · 24d ago
- Astellas links up with AI Proteins in $400M computational drug discovery dealJapan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially worth $400 million.fiercebiotech · 1mo ago
- Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsLooking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology’s masked T-cell engager tech in a potential $1.9 billion biobucks deal.fiercebiotech · 1mo ago
- Kairos seizes moment to push prostate cancer prospect into earlier settingKairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival data.fiercebiotech · 1mo ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 3mo ago
- Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate CancerDr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus on radium…onclive · 6mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 6mo ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that